Saturday, August 12, 2017 5:29:20 PM
Yes, the Anavex sigma-1 receptor agonist molecules, at least the major ones being used in new human trials (only Anavex 2-73 right now), and later. Anavex 3-71, are apparently very similar.
Regardless, if they are different only by a single hydroxide transposed to a new position (among the many dozens of them) FDA would require separate, individual testing for each form of molecule being proposed for approval.
Most likely, such minor changes would not materially change or affect clinical outcomes. Still, FDA has an obligation to make certain that new, minor re-configurations of the molecule are equally safe and efficacious.
Read typical drug molecule patent application text. First will be the lengthy, detailed chemical description of the molecule, in several forms. Most detailed are the chemical names, and then a graphic representation (molecular or structural model).
The proper, complete chemical name of Anavex 2-73 is tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride.
(Would be fun to say that at a cocktail party, when telling the profound future of Anavex. But, no, I don’t do that. I haven’t memorized it. No good purpose. I’ve memorized the Latin names of several hundred plants and animals I work with professionally. My favorite is Silphium terebinthinaceum. Look it up. Great plant.)
Anavex 3-71 is an enantiomer (specific configuration) of this molecule: (2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1Hindol-3-yl)propan-1-one .
Patent drug applications also commonly have text seeking patent protection not only for the specific molecule described and named in the application, but also for any similar molecule that has been chemically modified in minor ways, such as simply moving a hydroxyl (-OH) to another position.
About Anavex for Autism.
Don’t know about this just yet. Because many of the causes of autism occur during cerebral development, at least partially in utero, I’m not certain the Anavex sigma-1 receptor agonists could prevent the neurological mis-connections or malfunctions of the condition. Diagnosis and treatment in utero might be problematic.
But don’t take this conjecture as a “no.” There are a good number of molecules in the Anavex pipeline, with perhaps more to come. I doubt that all have been sufficiently tested in murine models for all of the human diseases that might be treated.
Anavex Life Sciences Corp may eventually have a giant stable of drugs innovatively treating a plethora of diseases and conditions not yet discussed concerning the company. Moreover, as I’ve contended previously, the company many be a great success not only for treatments, but for disease and condition prophylaxis, prevention.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM